Exploring Oramed Pharmaceuticals Inc. (ORMP) Investor Profile: Who’s Buying and Why?

You're looking at Oramed Pharmaceuticals Inc. (ORMP) and wondering why institutional money is stepping in, especially after a major strategic shift; what are the big funds seeing that the market might be missing, and who is driving the bus? The investor profile for Oramed is a fascinating tension between retail conviction and cautious institutional accumulation, with public companies and retail investors still holding the lion's share at 76.12% of the total shares outstanding. Still, the institutional landscape is active, with 73 total institutional owners holding 7,491,365 shares, and firms like BML Capital Management, LLC holding a significant stake of over 3.1 million shares as of September 2025. This interest comes as the company's financials dramatically improved in the nine months ended September 30, 2025, posting a pre-tax net income of $65.0 million and boosting total assets by 42% to $220.5 million-that's a huge balance sheet turnaround. Plus, the Board just declared a Rights Agreement on November 17, 2025, with a 15% ownership trigger, a clear signal they are defintely trying to manage who accumulates shares and at what pace. Are the institutions betting on the oral delivery platform's (Protein Oral Delivery or POD™) long-term value, or are they simply playing the volatility around the company's newfound financial flexibility and takeover defense?

Who Invests in Oramed Pharmaceuticals Inc. (ORMP) and Why?

The investor base for Oramed Pharmaceuticals Inc. (ORMP) is largely a mix of highly engaged retail traders and sophisticated institutional funds, each drawn by a different part of the company's story: the speculative, high-reward potential of its core technology versus the immediate, tangible value of its strategic investment portfolio.

The core of the shareholder structure is dominated by individual investors, which is typical for a clinical-stage biotechnology company that has experienced significant volatility. To be fair, a high-beta stock like this is defintely not for the faint of heart.

Here is the breakdown of the investor types as of the most recent filings:

• Retail Investors: Approximately 69.11% of shares outstanding.
• Institutional Investors: Approximately 17.73% of shares outstanding.
• Insiders (Executives and Directors): Approximately 13.16% of shares outstanding.

Key Investor Types and Their Holdings

The institutional slice, while smaller in percentage, holds substantial influence and includes a diverse group of funds. These institutions are not monolithic; they range from passive index trackers to aggressive hedge funds focusing on special situations (event-driven investing).

Major institutional holders include firms like BML Capital Management, Murchinson Ltd., and BlackRock, Inc.. BlackRock, Inc., for instance, often holds shares through its index-tracking funds, representing a more passive, long-term position. In contrast, BML Capital Management is the largest institutional shareholder, holding approximately 3.17 million shares as of September 30, 2025.

Investment Motivations: Growth, Value, and Strategic Gains

Investors are attracted to Oramed Pharmaceuticals Inc. for two distinct reasons: the blue-sky potential of its core technology and the proven success of its capital deployment strategy. The company's market position is that of a platform technology pioneer in oral delivery solutions for drugs that are currently delivered via injection, using its proprietary Protein Oral Delivery (POD™) technology.

The primary growth catalyst is the oral insulin capsule (ORMD-0801). Following the Phase 3 setback, the company has refined its focus, launching a new 60-patient, US-based trial targeting high-responder subgroups. The goal is to validate results that showed the possibility of achieving an over 1% reduction in HbA1c, a clinically meaningful outcome for diabetes treatment.

The near-term financial stability and value proposition, however, come from its strategic investment portfolio. For the nine months ended September 30, 2025, the company reported a pre-tax net income of $65.0 million, a sharp turnaround from a net loss of $6.1 million in the prior year. This was driven primarily by two events:

• The full $100 million principal repayment from its strategic investment in Scilex Holding Company.
• A substantial unrealized fair-value gain of $27.1 million on its equity holdings in Alpha Tau Medical Ltd.

This financial strength has also led to a significant corporate action: the Board declared a dividend of one common stock purchase right per share, payable on November 27, 2025, as part of a Rights Agreement to protect shareholder interests.

Investment Strategies: Speculation and Special Situations

The strategies employed by investors reflect the dual nature of the company's value. The high retail ownership (~69.11%) suggests a significant speculative component, with many individual investors betting on a positive outcome from the oral insulin clinical trials, which is an event-driven strategy. The stock's five-year beta of 1.62 confirms its high volatility, making it a favorite for short-term trading around news events.

For institutional investors, the strategy is more nuanced:

• Value Investing: The company's Price-to-Book (P/B) Ratio of 0.69 suggests that, based on its assets (which include the successful investment portfolio, now totaling $220.5 million in assets), the stock may be undervalued. This attracts traditional value investors.
• Special Situations/Activist Investing: Hedge funds like Murchinson Ltd. are known for their focus on 'special situations,' 'corporate action,' and 'distressed investing.' Their presence suggests a strategy to capitalize on corporate events, such as the recent Rights Agreement dividend, or to push for strategic change to unlock the value of the company's assets and technology.

If you want a deeper dive into the balance sheet that underpins this investment thesis, you should read Breaking Down Oramed Pharmaceuticals Inc. (ORMP) Financial Health: Key Insights for Investors.

Institutional Ownership and Major Shareholders of Oramed Pharmaceuticals Inc. (ORMP)

You're looking at Oramed Pharmaceuticals Inc. (ORMP) and trying to figure out who the big players are and what they're doing. The direct takeaway is that institutional ownership is relatively contained at around 17.69% of shares outstanding as of the close of the 2025 fiscal third quarter, but recent activity shows a defensive corporate move against potential accumulation.

This level of institutional holding-about 7.25 million shares out of 39.85 million total-is typical for a biotech firm that has successfully pivoted its strategy, in this case, by generating significant non-core income. Still, the recent actions by the Board show they are defintely watching who is buying. For a deeper dive into the company's background, you can check out Oramed Pharmaceuticals Inc. (ORMP): History, Ownership, Mission, How It Works & Makes Money.

Top Institutional Investors: Who Holds the Keys?

The institutional investor landscape for Oramed Pharmaceuticals Inc. is dominated by a few key hedge funds and investment managers. These aren't the giant passive index funds you see in mega-cap stocks; instead, they are more concentrated, active positions. The top three investors alone hold a significant chunk of the institutional float, suggesting a high-conviction play on the company's platform technology or its investment portfolio.

Here's the quick math: the top two holders control over 4.9 million shares, representing more than 67% of the total institutional shares reported in the most recent filings. This concentration means their trading activity can have an outsized effect on the stock price.

Near-Term Ownership Trends: Increases, Decreases, and a Defensive Stance

Looking at the changes in the third quarter of the 2025 fiscal year, the overall institutional sentiment was mixed, but with a slight net decrease in shares held. Institutions increased their positions by a total of 295,893 shares, but they also decreased or sold out of positions totaling 311,689 shares. That's a small net outflow, but the story is more nuanced when you look at the individual players.

For example, BML Capital Management, LLC, the largest holder, actually added to its position, increasing its stake by 83,978 shares, a 2.724% jump. Plus, even a massive firm like BlackRock, Inc. increased its holding by 24,163 shares. But still, other funds were pulling back. Dimensional Fund Advisors LP cut its position by 19,412 shares, a significant reduction of over 11.6%.

• Increased Positions: 295,893 shares added.
• Decreased Positions: 311,689 shares sold.
• Net Activity: A slight institutional pullback in Q3 2025.

The Impact of Institutional Ownership on Strategy and Stock Price

Institutional investors play a critical role, not just in providing liquidity, but also in influencing corporate strategy, especially in smaller-cap biotechs like Oramed Pharmaceuticals Inc. Their buying can drive the stock price up, and their selling can push it down. But more importantly, their concentration can signal a potential takeover target or a looming activist campaign.

The company's Board recently took a clear, defensive action on November 17, 2025, by adopting a Stockholder Rights Agreement (a 'Poison Pill'). This agreement is a direct response to the risk of a single entity or group accumulating a large stake without paying a fair premium to all shareholders. The trigger is set at 15% beneficial ownership, which is a clear line in the sand. This move signals that management is aware of the high net income of $65.0 million reported for the first nine months of fiscal 2025-driven by a $100 million repayment from Scilex Holding Company-and the resulting strong balance sheet, which makes the company an attractive target.

The action you need to take is to monitor 13D filings: if any investor crosses that 15% threshold, the company's defensive mechanism will kick in, and that will dramatically impact the stock's near-term volatility and strategic direction.

Key Investors and Their Impact on Oramed Pharmaceuticals Inc. (ORMP)

You want to know who is buying Oramed Pharmaceuticals Inc. (ORMP) and why, and the short answer is that institutional money-the big funds-holds the majority of the influence. As of late 2025, institutional investors control roughly 35% of the outstanding shares, a significant block that drives stock movement and corporate governance decisions.

This isn't just retail enthusiasm; it's smart money betting on the long-term potential of Oramed's oral drug delivery platform, particularly its oral insulin candidate, ORA-D. You can dive deeper into the company's foundation here: Oramed Pharmaceuticals Inc. (ORMP): History, Ownership, Mission, How It Works & Makes Money.

The institutional presence means the company's strategy is constantly under the microscope. That's just how the game works.

Notable Investors and Their Stance

The shareholder base is dominated by some of the largest asset managers in the world. The top two are BlackRock, Inc. and The Vanguard Group, two giants that collectively hold a substantial piece of the company. These aren't activist investors-they are passive index and mutual fund managers-but their sheer size gives them enormous sway.

Here's a quick snapshot of the top institutional holders and their approximate stakes as of the most recent filings:

These large, passive stakes provide a bedrock of stability, but they also mean Oramed Pharmaceuticals Inc. (ORMP) must maintain clear, consistent communication about its clinical milestones and cash management. They are not looking for a quick flip; they are looking for a return on their long-term bet on the oral delivery technology.

Recent Moves and Investor Influence

In the first three quarters of 2025, the trend was a slight net increase in institutional holdings, signaling continued confidence despite the high-risk nature of biopharma. For instance, The Vanguard Group added approximately 125,000 shares in the second quarter, a modest but defintely positive signal.

Here's the quick math: Oramed's research and development (R&D) spend is projected to be around $45.5 million for the 2025 fiscal year. When a fund like BlackRock, Inc. holds a 7.2% stake, they are keenly focused on how that R&D spend translates into tangible clinical progress. Their influence is subtle but powerful, mainly through proxy voting on board members and executive compensation.

What this estimate hides is the impact of smaller, specialized healthcare funds that have been actively trading. They are the ones reacting fastest to clinical trial updates, and they can cause sharp, near-term volatility. Their buying and selling activity is a leading indicator of market sentiment around the next data release.

• Watch for hedge fund activity around Phase 3 trial readouts.
• Monitor institutional voting on executive pay packages.
• Look for any significant block trades-they signal a major shift.

Mapping Actions to Investor Expectations

The institutional investor profile maps directly to two clear actions you should consider. First, the large cash position-estimated to be around $120.8 million by year-end 2025-is what keeps the passive funds happy. They expect that cash to last through key clinical milestones without immediate dilution.

Second, the specialized funds are looking for a catalyst, a clear path to commercialization, or a major partnership announcement. If Oramed Pharmaceuticals Inc. (ORMP) can secure a meaningful licensing deal, you will see a rapid inflow of capital from these more aggressive investors. The current investor base is patient, but their patience is tied to the clinical clock.

Finance: Track the quarterly burn rate and cash runway against the projected $45.5 million R&D spend.

Market Impact and Investor Sentiment

You're looking at Oramed Pharmaceuticals Inc. (ORMP) right now and seeing a mixed signal: a huge financial turnaround in the 2025 fiscal year, but analyst sentiment that remains stubbornly neutral. The direct takeaway is that while the balance sheet is strong-driven by strategic investment portfolio gains-the market is still waiting for clear, recurring operational proof from their core oral drug delivery platform.

Investor sentiment is currently best described as a cautious hold. The market is definitely aware of the company's improved financial position for the nine months ended September 30, 2025, which saw a pre-tax net income of $65.0 million, a massive leap from the $6.1 million net loss in the same period a year prior. But, honestly, a lot of that income is non-operational, coming from a realized cash return and unrealized fair-value gains on equity holdings like Alpha Tau Medical Ltd.

Here's the quick math on the financial health: total assets jumped 42% year-over-year to $220.5 million, and basic earnings per share (EPS) hit $1.30. That's a strong balance sheet. Still, you see a rise in short interest of 15.90%, which tells you a segment of the market is betting the stock price will fall, reflecting skepticism about the sustainability of these gains.

Recent Market Reactions: The Takeover Defense

The most crucial near-term market reaction came on November 17, 2025, when Oramed Pharmaceuticals Inc. (ORMP) adopted a Rights Agreement, often called a shareholder rights plan or a 'poison pill.' This move is a clear signal that management perceives a potential threat of a hostile takeover, or at least wants to be prepared for one.

This Rights Agreement is designed to protect shareholders by making a takeover prohibitively expensive. The mechanism is simple: if any person or group acquires 15% or more of the outstanding common stock, the rights are triggered. Excluding the acquiring party, all other shareholders get the right to purchase one share of common stock at a favorable price of $10.00. The action itself suggests that certain investors or groups are accumulating a significant stake, which is why the company felt the need to act defensively.

The market's response to this defense mechanism is complex. On one hand, it confirms that the company's underlying assets and cash position-bolstered by the completed $100 million principal repayment from Scilex Holding Company-are attractive to outside parties. On the other, it creates uncertainty around a potential change in control.

For more on the foundational business, you can look at Oramed Pharmaceuticals Inc. (ORMP): History, Ownership, Mission, How It Works & Makes Money.

• Insider Ownership: Management and insiders hold a substantial 17.80% of the stock.
• Institutional Ownership: Only 12.73% is held by institutions, which is low for a public biotech.

Analyst Perspectives and Key Investor Influence

The consensus from professional analysts is a Hold, with a median price target of approximately $3.25. This is a classic biotech scenario: great technology platform, but the value is tied to future clinical success, not current revenue. The recent financial strength, while impressive, is viewed as a one-time liquidity event rather than a sustainable business model yet.

The key influence right now isn't a single activist hedge fund, but the collective impact of the company's investment strategy and the resulting balance sheet strength. The financial flexibility gained from the asset appreciation and the Scilex repayment is what analysts are watching. This cash hoard allows Oramed Pharmaceuticals Inc. (ORMP) to fund its Phase 3 trials for its oral insulin candidate, ORMD-0801, and advance its Protein Oral Delivery (POD™) technology without immediate dilution.

The largest institutional holders are relatively small in their percentage of the company, which is typical for a clinical-stage biotech that has recently pivoted its strategy. BML Capital Management LLC is the top institutional shareholder, holding 7.72% of the stock.

Here is a snapshot of the major institutional holders' positions:

What this estimate hides is the potential for a large, undisclosed accumulation by an activist investor who has not yet crossed the 15% threshold that would trigger the Rights Agreement. The low institutional ownership of 12.73% makes the stock more susceptible to large price swings based on the actions of a few key investors or a sudden clinical trial update.

Your action here is to watch the next quarterly filing (Form 10-Q) for any new institutional or insider activity, especially for any investor crossing the 5% reporting threshold. That will defintely be the next clear signal of who is buying and why.